Novel Vascular Disrupting AgentsAre Coming of Age

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancers, such as ovarian and certain thyroid cancers. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors. OXiGENE is dedicated to leveraging its scientific expertise, intellectual property and therapeutic development capabilities to bring life-extending and life-enhancing medicines to patients.

Welcome From Our New CEO

Click here to read a shareholder letter from Oxigene’s new President and Chief Executive Officer, Dr. Dai Chaplin.

Dr. Chaplin is a prominent tumor biologist who pioneered early work related to vascular disrupting agents.

Compelling Pipeline

After many years of research, we believe that fosbretabulin is poised to become the first commercialized VDA, having shown meaningful clinical activity and tolerability in clinical trials to date.

Click here to see our diverse pipeline.

About VDAs

Vascular Disrupting Agents or “VDAs” block blood flow through established tumor blood vessels, thereby starving tumors of oxygen and essential nutrients, leading to tumor cell death.

Watch a video to learn more about this novel approach.